



Noxopharm and UNSW Pancreatic Cancer Research Accepted at Leading US Conference

- **Noxopharm and University of New South Wales to present pancreatic cancer research**
- **Chroma™ drug candidates tested with pioneering patient explant model using tissue taken from pancreatic cancer patients during surgery**
- **Low survival rates mean urgent need for better treatments in pancreatic cancer**

Sydney, 16 August 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** and the University of New South Wales (UNSW Sydney) announce research from the Chroma™ program has been selected to feature at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer.

The research will appear as a conference poster accompanied by a video presentation, and relates to Noxopharm's proprietary drug candidates within the Chroma™ technology platform, which are demonstrating promising efficacy signals against pancreatic cancer.

In collaboration with UNSW, the testing of these drug candidates is being performed with an innovative, state-of-the-art patient explant model that uses cancer tissues taken from pancreatic cancer patients during surgery. This model is the first of its kind and creates a unique new opportunity in researching potential treatments for pancreatic cancer, as described in a recent [publication in *Scientific Reports*](#), a highly regarded *Nature* journal that was the fifth most cited journal in the world last year.

Professor Phoebe Phillips, the lead pancreatic cancer researcher from UNSW, said: "Our explant model enables us to not only grow the tumour cells by themselves, but also the surrounding scar-tissue 'fortress', which represents a much closer real-life situation than any other model and is advantageous in testing drug candidates. Results using Noxopharm's Chroma™ compounds in our explant model are looking promising, and we will continue to investigate whether these compounds can be translated to the clinic. We are pleased to be able to share our work with Noxopharm with such an eminent international audience."

Noxopharm CEO Dr Gisela Mautner said: "It is very encouraging to have this abstract accepted by such a prestigious US conference, as it helps raise the international profile of Noxopharm and UNSW, demonstrates the value of the explant model, and shows the potential of our pre-clinical drug candidates.

"Pancreatic cancer is highly aggressive, with low survival rates and one of the highest mortality rates among the major cancers. There is therefore an urgent need to develop more effective treatments, especially as so few currently exist."

The AACR's Special Conference on Pancreatic Cancer is a leading cancer forum that attracts approximately 500 global leaders in pancreatic cancer research and treatment, and covers



the latest cutting-edge advances in the field. It will take place from 13-16 September 2022 in Boston, Massachusetts.

Noxopharm – UNSW AACR Abstract:

Title: *CRO-[XX] is a novel therapeutic for pancreatic cancer: implications for tumour and stromal reprogramming*

Authors: Kokkinos J¹, Sharbeen G¹, Haghighi KS², Youkhana J¹, Raina A¹, Pitiyarachchi O¹, Truong, Q³, Wenholz, D^{3,4}, Laczka, O³, Kumar, N⁴, Goldstein D^{1,2}, Phillips PA¹.

¹*Pancreatic Cancer Translational Research Group, School of Medical Sciences, Lowy Cancer Research Centre, UNSW Sydney.*

²*Prince of Wales Hospital, School of Clinical Medicine, Randwick Clinical Campus, UNSW Sydney.*

³*Noxopharm Limited, Sydney.*

⁴*School of Chemistry, UNSW Sydney.*

UNSW's Disclaimer and Conflict of Interest Statement

This work is funded by Noxopharm via contract research arrangement and is still in progress. Despite the promising results obtained to date, UNSW acknowledges these therapeutic candidates are and will be subject to further safety and efficacy preclinical and clinical studies.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda[®], plus two innovative technology platforms – Chroma[™] (oncology) and Sofra[™] (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.